ganaxolone (Ztalmy) Report issue

Small molecule Orphan Drug FDA Approved FDA Priority Review FDA
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Ganaxolone, sold under the brand name Ztalmy, is a medication used to treat seizures in people with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD).   Wikipedia

Chemistry

  • SMILES: CC(=O)[C@H]1CC[C@H]2[C@@H]3CC[C@H]4C[C@](C)(O)CC[C@]4(C)[C@H]3CC[C@]12C
  • InChIKey: PGTVWKLGGCQMBR-FLBATMFCSA-N
  • Mol. Mass: 332.53
  • ALogP: 4.99
  • ChEMBL Molecule:
    ganaxolone  
More Chemistry

Pharmacology

Alternative names

3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one | ccd 1042 | ccd-1042 | ganaxolone

Organizations (10)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (21)

Approved Indications (1)


 

Seizures (approved 2022)

Experimental Indications - Clinical Trial Phases 1-4 (21)


 

Behavioral Symptoms (Phase 2)

Deficiency Diseases (Phase 3)

Depression (Phase 2)

Depression, Postpartum (Phase 2)

Depressive Disorder (Phase 2)

Epilepsies, Partial (Phase 2)

Epilepsy (Phase 3)

Epilepsy, Complex Partial (Phase 2)

Fragile X Syndrome (Phase 2)

Mental Disorders (Phase 2)

Mood Disorders (Phase 2)

Postpartum Period (Phase 2)

Pregnancy Complications (Phase 2)

Puerperal Disorders (Phase 2)

Seizures (Phase 3)

Smoking Cessation (Phase 2)

Spasms, Infantile (Phase 2)

Status Epilepticus (Phase 3)

Stress Disorders, Post-Traumatic (Phase 2)

Tuberculin (Phase 2)

Tuberous Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 21
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue